KKR announced August 3 it will acquire Integer Holdings in an all-cash transaction valued at approximately $5.7 billion, including debt assumption. Integer supplies cardiac rhythm management devices and neuromodulation components to medtech OEMs including Medtronic, Boston Scientific, and Abbott. The deal marks KKR's largest healthcare take-private since its $4.6 billion Envision Healthcare acquisition in 2018 and follows eighteen months of concentrated buying in the medical-device supply chain.
Integer recorded $1.48 billion in trailing-twelve-month revenue as of Q1 2025, operating two divisions: Cardio & Vascular (62% of revenue) and Portable Medical (38%). The company manufactures batteries, leads, enclosures, and components for implantable devices—low-margin, high-reliability work that large OEMs increasingly outsource. Integer's EBITDA margin held at 18.2% in 2024, compressed from 19.7% in 2022 as titanium and lithium costs rose 14% year-over-year. Public equity investors penalized the margin erosion; Integer shares traded at 11.3x forward EBITDA before deal rumors surfaced in mid-July.
KKR's thesis appears operational, not financial engineering. The firm has acquired six medical-device suppliers since January 2023, including surgical instrument maker Aesculap's distribution arm and infusion-pump component manufacturer Fresenius Kabi's device unit. Integer's customer concentration—Medtronic represents 22% of revenue, Boston Scientific 16%—mirrors the oligopoly structure KKR now serves across multiple portfolio companies. Taking Integer private eliminates quarterly earnings volatility and allows multi-year capital deployment into manufacturing automation. Integer's Tijuana and Juarez facilities, which produce 41% of company output, require roughly $220 million in incremental capex to automate battery-cell assembly and reduce reliance on manual enclosure welding, according to the company's 2024 investor day materials. Public markets rarely reward three-year payback automation projects; private equity can afford the patience.
The deal structure matters for medical-device allocators. Integer's enterprise value implies 13.8x LTM EBITDA, a 190-basis-point premium to publicly traded peers like TE Connectivity's medical division and Greatbatch's successor entities. KKR is paying for Integer's FDA-registered facilities and existing design-transfer agreements with OEMs—regulatory moats that take thirty to forty-eight months to replicate. If KKR consolidates Integer's purchasing with its other device suppliers, the combined entity could command 8-12% better pricing on titanium alloys and lithium chemistries, enough to restore EBITDA margins to 20% within eighteen months. That margin recovery, if executed, would justify the purchase multiple and set a new valuation floor for publicly traded device suppliers still trading at 9-11x EBITDA.
Operators should monitor two follow-on events. First, whether Integer's top-three OEM customers renegotiate supply agreements before deal close, expected in Q4 2025 pending HSR clearance and CFIUS review. Device OEMs historically insert change-of-control provisions that allow price reopeners; any disclosed amendments in Integer's proxy filing will signal whether KKR negotiated pricing stability upfront. Second, watch KKR's other device suppliers for bolt-on acquisitions in Q1 2026. The firm now controls enough component capacity to pursue vertical integration into subassembly work—higher-margin, stickier contracts that could compress publicly traded specialists like Nordson Medical or Cirtec.
Integer's exit leaves $18 billion in remaining public market cap across pure-play device component suppliers, down from $31 billion in early 2022. Private equity has removed seven such companies in thirty months.